Doping control analysis of selected peptide hormones using LC-MS(/MS)

Forensic Science International

Volumn 213, Issue 1-3, 2011, Pages 35-41

  Thevis, Mario ^a   Thomas, Andreas ^a   Schänzer, Wilhelm ^a  

^a GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

Author keywords

Doping; IGF 1; Mass spectrometry; Peptide hormones; Sport

Indexed keywords

GROWTH HORMONE RELEASING FACTOR; HUMAN GROWTH HORMONE; INSULIN ASPART; INSULIN GLULISINE; INSULIN LISPRO; PEPTIDE HORMONE; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN;

ACCURACY; AMINO ACID SEQUENCE; ANALYTIC METHOD; ANALYZER; ARTICLE; BLOOD ANALYSIS; DOPING; DRUG CONTROL; DRUG MISUSE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONE DETERMINATION; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETER; MOLECULAR WEIGHT; MULTIPLE DRUG ABUSE; PRIORITY JOURNAL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SPORTS MEDICINE; TANDEM MASS SPECTROMETRY; URINALYSIS;

EID: 80655149118     PISSN: 03790738     EISSN: 18726283     Source Type: Journal    
DOI: 10.1016/j.forsciint.2011.06.015     Document Type: Article

References (45)

1. Thevis M. Mass Spectrometry in Sports Drug Testing - Characterization of Prohibited Substances and Doping Control Analytical Assays 2010, Wiley, Hoboken.
2. M. Thevis, A. Thomas, W. Schänzer, Current role of LC-MS(/MS) in doping control, Anal. Bioanal. Chem., doi:10.1007/s00216-00011-04859-00219.
3. Thevis M., Schänzer W. Identification and characterization of peptides and proteins in doping control analysis. Curr. Proteomics 2005, 2:191-208.
4. Thevis M., Schänzer W. Mass spectrometric identification of peptide hormones in doping control analysis. Analyst 2007, 132:287-291.
5. Thevis M., Thomas A., Schänzer W. Insulin. Handb. Exp. Pharmacol. 2010, 195:209-226.
6. Green R.P., Hollander A.S., Thevis M., Thomas A., Dietzen D.J. Detection of surreptitious administration of analog insulin to an 8-week-old infant. Pediatrics 2010, 125:e1236-e1240.
7. Thomas A., Kohler M., Schänzer W., Delahaut P., Thevis M. Determination of IGF-1 and IGF-2, their degradation products and synthetic analogues in urine by LC-MS/MS. Analyst 2011, 136:1003-1012.
8. Thevis M., Schänzer W. Current role of LC-MS(/MS) in doping control. Anal. Bioanal. Chem. 2007, 388:1351-1358.
9. Holt R.I., Sonksen P.H. Growth hormone, IGF-I and insulin and their abuse in sport. Br. J. Pharmacol. 2008, 154:542-556.
10. Thevis M., Thomas A., Delahaut P., Bosseloir A., Schanzer W. Doping control analysis of intact rapid-acting insulin analogues in human urine by liquid chromatography-tandem mass spectrometry. Anal. Chem. 2006, 78:1897-1903.
11. Thevis M., Thomas A., Delahaut P., Bosseloir A., Schänzer W. Qualitative determination of synthetic analogues of insulin in human plasma by immunoaffinity purification and liquid chromatography-tandem mass spectrometry for doping control purposes. Anal. Chem. 2005, 77:3579-3585.
12. Thomas A., Thevis M., Delahaut P., Bosseloir A., Schänzer W. Mass spectrometric identification of degradation products of insulin and its long-acting analogues in human urine for doping control purposes. Anal. Chem. 2007, 79:2518-2524.
13. Thevis M., Thomas A., Schänzer W. Mass spectrometric determination of insulins and their degradation products in sports drug testing. Mass Spectrom. Rev. 2008, 27:35-50.
14. Thomas A., Schänzer W., Delahaut P., Thevis M. Sensitive and fast identification of urinary human, synthetic and animal insulin by means of nano-UPLC coupled with high resolution/high accuracy mass spectrometry. Drug Test. Anal. 2009, 1:219-227.
15. Sonksen P.H. Hormones and sport (insulin, growth hormone and sport). J. Endocrinol. 2001, 170:13-25.
16. Darby S.M., Miller M.L., Allen R.O., LeBeau M. A mass spectrometric method for quantitation of intact insulin in blood samples. J. Anal. Toxicol. 2001, 25:8-14.
17. Kippen A.D., Cerini F., Vadas L., Stöcklin R., Vu L., Offord R.E., Rose K. Development of an isotope dilution assay for precise determination of insulin, C-peptide, and proinsulin levels in non-diabetic and Type II diabetic individuals with comparison to immunoassays. J. Biol. Chem. 1997, 272:12513-12522.
18. Chamberlain M.J., Stimmler L. The renal handling of insulin. J. Clin. Invest. 1967, 46:911-919.
19. Du B.H., Eng J., Yalow R.S. Methods for concentration of urinary immunoreactive insulin. J. Korean Med. Sci. 1986, 1:1-4.
20. Kanu A.B., Dwivedi P., Tam M., Matz L., Hill H.H. Ion mobility-mass spectrometry. J. Mass Spectrom. 2008, 43:1-22.
21. Ghigo E., Arvat E., Muccioli G., Camanni F. Growth hormone-releasing peptides. Eur. J. Endocrinol. 1997, 136:445-460.
22. World Anti-Doping Agency, The 2011 Prohibited List, (27-10-10). http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/To_be_effective/WADA_Prohibited_List_2011_EN.pdf.
23. Okano M., Nishitani Y., Sato M., Ikekita A., Kageyama S. Influence of intravenous administration of growth hormone releasing peptide-2 (GHRP-2) on detection of growth hormone doping: growth hormone isoform profiles in Japanese male subjects. Drug Test. Anal. 2010, 2:548-556.
24. Matschiner S. Grenzwertig 2011, RIVA Sportverlag, Wien.
25. Thomas A., Guddat S., Kohler M., Krug O., Schänzer W., Petrou M., Thevis M. Comprehensive plasma-screening for known and unknown substances in doping controls. Rapid Commun. Mass Spectrom. 2010, 24:1124-1132.
26. A. Thomas, S. Hoppner, H. Geyer, W. Schanzer, M. Petrou, D. Kwiatkowska, A. Pokrywka, M. Thevis, Determination of growth hormone releasing peptides (GHRP) and their major metabolites in human urine for doping controls by means of liquid chromatography mass spectrometry, Anal. Bioanal. Chem., doi:10.1007/s00216-00011-04702-00213.
27. Okano M., Sato M., Ikekita A., Kageyama S. Determination of growth hormone secretagogue pralmorelin (GHRP-2) and its metabolite in human urine by liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2010, 24:2046-2056.
28. Kohler M., Thomas A., Geyer H., Petrou M., Schanzer W., Thevis M. Confiscated black market products and nutritional supplements with non-approved ingredients analyzed in the Cologne Doping Control Laboratory 2009. Drug Test. Anal. 2010, 2:533-537.
29. Henninge J., Pepaj M., Hullstein I., Hemmersbach P. Identification of CJC-195, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test. Anal. 2010, 2:647-650.
30. Thomas A., Kohler M., Mester J., Geyer H., Schänzer W., Petrou M., Thevis M. Identification of the growth-hormone-releasing peptide-2 (GHRP-2) in a nutritional supplement. Drug Test. Anal. 2010, 2:144-148.
31. Erotokritou-Mulligan I., Holt R.I. Insulin-like growth factor I and insulin and their abuse in sport. Endocrinol. Metab. Clin. North Am. 2010, 39:33-43. viii.
32. Holt R.I.G. Detecting growth hormone abuse in athletes. Drug Test. Anal. 2009, 1:426-433.
33. Sinner D. Anabole Steroide - Das Schwarze Buch 2007, BMS Verlag, Gronau.
34. Popot M.A., Woolfitt A.R., Garcia P., Tabet J.C. Determination of IGF-I in horse plasma by LC electrospray ionisation mass spectrometry. Anal. Bioanal. Chem. 2008, 390:1843-1852.
35. Bredehöft M., Schänzer W., Thevis M. Quantification of human insulin-like growth factor-1 and qualitative detection of its analogues in plasma using liquid chromatography/electrospray ionisation tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2008, 22:477-485.
36. de Kock S.S., Rodgers R.P., Swanepoel B.C. Growth hormone abuse in the horse: preliminary assessment of a mass spectrometry procedure for IGF-1 identification and quantitation. Rapid Commun. Mass Spectrom. 2001, 15:1191-1197.
37. Kay R.G., Barton C., Velloso C.P., Brown P.R., Bartlett C., Blazevich A.J., Godfrey R.J., Goldspink G., Rees R., Ball G.R., Cowan D.A., Harridge S.D., Roberts J., Teale P., Creaser C.S. High-throughput ultra-high-performance liquid chromatography/tandem mass spectrometry quantitation of insulin-like growth factor-I and leucine-rich alpha-2-glycoprotein in serum as biomarkers of recombinant human growth hormone administration. Rapid Commun. Mass Spectrom. 2009, 23:3173-3182.
38. Pan S., Aebersold R., Chen R., Rush J., Goodlett D.R., McIntosh M.W., Zhang J., Brentnall T.A. Mass spectrometry based targeted protein quantification: methods and applications. J. Proteome Res. 2009, 8:787-797.
39. Kicman A.T., Cowan D.A. Peptide hormones and sport: misuse and detection. Br. Med. Bull. 1992, 48:496-517.
40. Kohler M., Thomas A., Walpurgis K., Terlouw K., Schänzer W., Thevis M. Detection of His-tagged Long-R(3)-IGF-I in a black market product. Growth Horm. IGF Res. 2010, 20:386-390.
41. Associated-Press, in Associated Press, Tallin, 2011.
42. Associated-Press, in Sports Illustrated, 2011.
43. Bidlingmaier M., Manolopoulou J. Detecting growth hormone abuse in athletes. Endocrinol. Metab. Clin. North Am. 2010, 39:25-32. vii.
44. Bidlingmaier M., Strasburger C.J. Growth hormone. Handb. Exp. Pharmacol. 2010, 195:187-200.
45. Hepner F., Cszasar E., Roitinger E., Lubec G. Mass spectrometrical analysis of recombinant human growth hormone (Genotropin(R)) reveals amino acid substitutions in 2% of the expressed protein. Proteome Sci. 2005, 3:1.